Legend Biotech Corporation American Depositary Shares

Legend Biotech (LEGN) stock fell 7.52% in premarket trading Thursday after the cell therapy company announced an underwritten public offering of 7.7 million American Depositary Shares at $29.35 per ADS, expected to raise approximately $226 million. The decline comes despite the company's strong market position and analyst Buy rating with a $58.57...

Legend Biotech Corporation announced the pricing of an underwritten public offering of 7.7 million American Depositary Shares at $29.35 per ADS, expected to raise approximately $226 million in gross proceeds. The offering is expected to close on June 23, 2026, with Morgan Stanley, Jefferies, Citigroup, and Deutsche Bank Securities serving as join...

Legend Biotech announced positive Phase 1 clinical data for LB2501, an investigational in vivo CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. The therapy achieved 100% objective response rate and 83.3% complete response rate at the higher dose level following a single infusion without lymphodepletion, with a favorable saf...

Legend Biotech (LEGN) surged 18% on Monday following bullish analyst updates from H.C. Wainwright and RBC Capital. The rally was partly inspired by Eli Lilly's $7 billion acquisition of Kelonia Therapeutics, a CAR-T therapy developer similar to Legend. Analysts highlighted Legend's promising pipeline programs, including encouraging progress on it...

Suvretta Capital Management sold nearly 1.1 million shares of Arcutis Biotherapeutics (ARQT) during Q3, reducing its position by $35.78 million. Despite the sale, ARQT remains the fund's largest holding worth $197.51 million. The stock has doubled in value over the past year, significantly outperforming the S&P 500. The sale appears to be a risk ...